SOURCE: Cambridge Healthtech Institute

Cambridge Healthtech Institute

June 02, 2016 13:00 ET

Keynote Speaker and Final Agenda Announced for Targeting Ocular Disorders 2016

Experts From Janssen, Genzyme, EyeGate Pharmaceuticals, Inc. and More Discuss the Most Promising Emerging Therapies in Ocular Disorders

NEEDHAM, MA--(Marketwired - June 02, 2016) - Cambridge Healthtech Institute (CHI), a division of Cambridge Innovation Institute, announced the speaker lineup and final agenda for the 4th Annual Targeting Ocular Disorders: The Latest Targets, Pathways and Drug Delivery Methods, taking place September 20-21, 2016 in Boston as part of the 14th Annual Discovery on Target.

This year's program provides a platform to discuss novel targets and disease pathways, the latest drug delivery methods, and the most promising emerging therapies with leading pharma and biotech companies working on a range of retinal diseases. A special focus will be on gene therapy, stem cell therapies, and treatments outside of the well-established anti-VEGF monotherapies.

The Keynote Presentation will be delivered by Justin Hanes, Ph.D., Lewis J. Ort Professor and Director of The Center for Nanomedicine at the Wilmer Eye Institute at Johns Hopkins University School of Medicine. Hanes, also the founder of Kala Pharmaceuticals and GrayBug Vision, has been named among "The World's Top 100 Young Innovators and Leaders in Technology and Business" by the MIT Technology Review and one of "The World's Most Influential Scientific Minds: 2014" by Thompson Reuters. At the Targeting Ocular Disorders conference Hanes discusses the dawn of nanotechnology in ocular therapeutics.

Justin Hanes will join leaders from Janssen, Genzyme, EyeGate Pharmaceuticals, Inc., Ophthotech, Ohr Pharmaceutical, Inc. and many more who look forward to sharing their knowledge, best practices, and expertise with all attendees. Their presentations will cover stem cells for ocular disorders, recent developments in gene therapy for retinal diseases, innovative drug delivery methods, and novel targets and disease pathways outside of conventional Anti-VEGF monotherapies.

For more information on Targeting Ocular Disorders, including a full speaker line-up and detailed agendas, visit: Healthtech.com/Targeting-Ocular-Disorders

About Cambridge Healthtech Institute (www.healthtech.com)
Cambridge Healthtech Institute (CHI), a division of Cambridge Innovation Institute, is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech, CROs, academia, and niche service providers. CHI is renowned for its vast conference portfolio held worldwide including PepTalk, Molecular Medicine Tri-Conference, SCOPE Summit, Bio-IT World Conference & Expo, PEGS Summit, Drug Discovery Chemistry, Biomarker World Congress, World Preclinical Congress, Next Generation Dx Summit and Discovery on Target. CHI's portfolio of products include Cambridge Healthtech Institute Conferences, Barnett International, Insight Pharma Reports, Cambridge Marketing Consultants, Cambridge Meeting Planners, Knowledge Foundation, Bio-IT World, Clinical Informatics News and Diagnostics World.

Contact Information